Biotech startup Transcell Biologics received undisclosed funding from IAN & Quantiphi
The Boston-based Quantiphi and the IAN Group have invested an undisclosed sum in the biotech startup Transcell Biologics.
According to a press release from Transcell Biologics, the money will be used to grow the company’s clientele and introduce Digital Animal Replacement Technology (DART) as an enterprise solution for the world’s bio and pharmaceutical industries.
Transcell Biologics was founded in 2009 by Subadra Dravida and focuses on increasing stem cell yield while maintaining pluripotency and functionality. It also provides a proprietary process and has expanded the range of uses for stem cell technologies.
The Hyderabad-based company claims that DART offers testing methods that do not require animal experimentation. It does this by combining AI/ML embedded in silico platform configurations with human MicroPhysiological Systems (hMPS) technology to automate and streamline the bioassay processes and produce reports that are statistically compliant. The purpose of the solution is to efficiently test safety and efficacy concerns related to medications and vaccines intended for human consumption.
According to Transcell Biologics, biopharmaceutical companies are incorporating its enterprise solution into their high-impact programs, demonstrating the significant traction that DART implementation has gained in Indian markets. The company wants to grow its clientele in Japan, Europe, and the United States.
